Study of hallucinations in Parkinson's disease, eye disease and dementia- trial feasibility
- Conditions
- Specialty: Dementias and neurodegeneration, Primary sub-specialty: DementiaUKCRC code/ Disease: Neurological/ Extrapyramidal and movement disorders, Neurological/ Other degenerative diseases of the nervous systemEye DiseasesDementias and neurodegeneration
- Registration Number
- ISRCTN14435750
- Lead Sponsor
- King's College London
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 10
1. 60+ years old
2. Sufficient fluency in English to participate in the interviews
3. Clinical diagnosis of dementia, eye disease or Parkinson’s disease.
4. Experience of visual hallucinations every two weeks over the 4 weeks prior to trial entry.
5. MMSE > 13
Exclusion Phase 1
1. Visual hallucinations accounted for by schizophrenia, epilepsy or narcolepsy
2. Participation in an interventional clinical trial in the previous 28 days.
3. Patients with dementia without a study partner.
Exclusion Phase 2
1. If prescribed a cholinesterase inhibitor as part of routine clinical care, contraindications or cautions to ondansetron (Congenital long QT syndrome; Adenotonsillar surgery; subacute intestinal obstruction; susceptibility to QT-interval prolongation (including electrolyte disturbances - see current summary of Product Characteristics)).
2. If not prescribed a cholinesterase inhibitor as part of routine clinical care, contra-indications or cautions to donepezil (Asthma; chronic obstructive pulmonary disease; sick sinus syndrome; supraventricular conduction abnormalities; susceptibility to peptic ulcers - see current Summary of Product Characteristics).
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method